The use of structured and semi-structured diagnostic instruments allows objective assessment of DSM categories by professionals involved in child and adolescent mental health evaluation, which has been essential to the advancement of clinical and epidemiological research in the field. Over the years, several semi-structured diagnostic instruments have been developed and tested for reliability and validity, such as the Diagnostic Interview for Children and Adolescents (DICA)[@B01]; the Development and Well-Being Assessment (DAWBA)[@B02]; and the Schedule for Affective Disorders and Schizophrenia for School-age Children (K-SADS).[@B03]

The K-SADS is among the most widely used instruments in child and adolescent psychiatry. The first version was the K-SADS present state (K-SADS-P), developed by J. Puig-Antich and W. Chambers in 1978. Updates and adaptations were published in the following decades: the K-SADS-P IIIR in accordance to DSM-IIIR criteria, as well as the K-SADS epidemiologic (K-SADS-E), which collects lifetime diagnoses for epidemiologic purposes. After publication of the DSM-IV in 1994, Kaufman, Birmaher, Brent, Rao, and Ryan introduced the K-SADS present and lifetime version (K-SADS-PL), which was the most comprehensive version developed to date.[@B03] The K-SADS-E and K-SADS-PL have been translated into Brazilian Portuguese, and have been used extensively by researchers and clinicians ever since.[@B04],[@B05]

In 2013, the American Psychiatry Association launched the fifth edition of the DSM, with relevant changes to the psychiatric classification of disorders affecting children and adolescents.[@B06],[@B07] Soon after, a revised version of the instrument (K-SADS-PL-DSM-5) was developed to keep the instrument up to date with the new classification system. However, this instrument has not yet been translated into Brazilian Portuguese, hindering the advancement of child and adolescent psychiatry research in the country. On that account, we endeavored to translate the revised K-SADS-PL-DSM-5 from English into Brazilian Portuguese.

In this letter, we describe the careful process of translation of the latest version of the K-SADS-PL, now updated according to current DSM-5 criteria (K-SADS-PL-DSM-5), for use in Brazil. We invited specialists in each diagnostic area covered by the instrument ([Table 1](#t01){ref-type="table"}) to translate the respective section. The entire text was then revised by two child and adolescent psychiatrists (TBMR and CK) and standardized by an independent professional (RK, a pediatrician and child neurologist with a background in linguistics). Subsequently, the translators of each area approved the final version of the document.

We regard this as a much-needed and relevant accomplishment, which should be followed by validation of this translated version. Scientific research is asymmetrically scarce in low- and middle-income countries,[@B08] where the health demands of children and adolescents are mostly unmet.[@B09] While many factors operate in this equation, we believe that the availability of up-to-date translated and validated versions of psychometric instruments used worldwide is an important step towards equality of means.
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###### Diagnostic categories covered in K-SADS-PL-DSM-5

  -------------------------------------------------------------
  Depressive and bipolar related disorders
   Depressive disorders
   Mania
   Disruptive mood dysregulation disorder
  Schizophrenia spectrum and other psychotic disorders
   Psychosis
  Anxiety, obsessive-compulsive, and trauma-related disorders
   Panic disorder
   Agoraphobia
   Separation anxiety disorder
   Social anxiety disorder and selective mutism
   Specific phobia
   Generalized anxiety disorder
   Post-traumatic stress disorder
   Obsessive-compulsive disorder
  Neurodevelopmental, disruptive and conduct disorders
   Attention-deficit/hyperactivity disorder
   Oppositional defiant disorder
   Conduct disorder
   Tic disorders
   Autism spectrum disorder
  Eating disorders and substance-related disorders
   Eating disorders
   Tobacco use disorder
   Alcohol use disorder
   Substance use disorder
  Others
   Enuresis
   Encopresis
  -------------------------------------------------------------
